Showing 851-860 of 10588 results for "".
Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice
https://reachmd.com/programs/cme/strategic-excellence-mastering-the-expanding-attr-cm-therapeutic-landscape-in-pharmacy-practice/18124/Enhance pharmacists' expertise in managing ATTR-CM with advanced knowledge and clinical insights for this evolving landscape.Hidden in Plain Sight: A Modern Guide to Detecting and Managing Early Neurotrophic Keratitis
https://reachmd.com/programs/cme/hidden-in-plain-sight-a-modern-guide-to-detecting-and-managing-early-neurotrophic-keratitis/54091/Can you detect NK early and accurately? Join our experts to learn about the most effective diagnostic strategies and best practices in the management of NK.The Do’s and Don’ts of Managing Pediatric Hidradenitis Suppurativa
https://reachmd.com/topics/rare-disease/the-dos-and-donts-of-managing-pediatric-hidradenitis-suppurativa/54450/Pediatric HS is often underrecognized, especially in prepubertal children, leading to delayed treatment and preventable disease progression. Clinicians should adapt diagnostic criteria and proactively screen high-risk groups, such as patients with severe acne. Children with HS frequently have assocPrognostic Tools in the Management of ADPKD
https://reachmd.com/programs/cme/prognostic-tools-in-the-management-of-adpkd/13877/This Expert Exchange webcast is designed to help improve clinicians’ ability to utilize prognostic tools to monitor disease progression and implement appropriate treatment strategies in patients with ADPKD. This activity is not available for continuing educBeyond the Joint: Cross-Specialty Solutions for Advancing TGCT Patient Care
https://reachmd.com/programs/cme/beyond-the-joint-cross-specialty-solutions-for-advancing-tgct-patient-care/36596/Explore TGCT recognition, clinical evidence, treatment strategies, and management of adverse events with CSF1R inhibitors in an interdisciplinary context.Gene Therapy, the Future of Eye Care?
https://reachmd.com/programs/medical-industry-feature/gene-therapy-future-of-eye-care/37246/While anti-VEGF therapy can deliver vision gains with consistent, frequent injections in clinical trials, it may be challenging to sustain this in real-world practice.1 Ocular gene therapy could be a potential option for patients with neovascular age-related macular degeneration if approved. With thDaily Contact Lenses for New and Existing Patients
https://reachmd.com/programs/empower/daily-contact-lenses-for-new-and-existing-patients/56896/A high-concept guide on getting patients into dailies, switching patients to a different daily, and ensuring that patients are equipped for success.Next-Generation Technology Built on a Trusted Legacy
https://reachmd.com/programs/modern-aesthetics/next-generation-technology-built-on-a-trusted-legacy/49014/How to Develop Interdisciplinary, Realistic Health Policies in an Era of Health System Reform
https://reachmd.com/programs/heart-matters/how-to-develop-interdisciplinary-realistic-health-policies-in-an-era-of-health-system-reform/6263/What can we learn from the past century of healthcare policy that can better inform how we develop such policies today? How has the landscape of medicine and economics surrounding health policy changed, and how have these changes influenced health policy? Join host Dr. Jack Lewin as he welcomes guesImproving Survival and Function in Pediatric TK2d with Nucleoside Therapy
https://reachmd.com/programs/clinicians-roundtable/improving-survival-and-function-in-pediatric-tk2d/37635/What if a rare, progressive neuromuscular disease like thymidine kinase 2 deficiency (TK2d) could not only be stabilized, but partially reversed? Based on findings from a pooled analysis of pediatric patients, pyrimidine nucleoside or nucleotide therapy reduced mortality risk up to 95%, with nearly